Although some patients required assistance during the training phase, most managed self-infusion and reported satisfaction in managing therapy autonomously. Educating patients with neuropathies to self-infuse high-dose SCIG at home and with flexibility in dosing schedules was successfully demonstrated in this patient group” Rasutis et al (2017).

Abstract:

Multifocal motor neuropathy (MMN), an immune neuromuscular condition causing progressive weakness, usually responds to immune-mediated treatments, including intravenous immunoglobulin (IVIG). Fifteen patients with MMN receiving IVIG were enrolled in an open-label, single-center trial and switched to 20% subcutaneous immunoglobulin (SCIG) using a smooth transition protocol (ie, changing the therapy without interruption or impact on the intended outcome of the therapy).

ReTweet if useful... High-dose subcutaneous immunoglobulin in patients with multifocal motor neuropathy https://ctt.ec/admix+ @ivteam #ivteam

Click To Tweet
Patients received individualized training and support based on motivation and ability to learn, follow directions, and maintain compliance. Although some patients required assistance
High-dose subcutaneous immunoglobulin in patients with multifocal motor neuropathy | 2

during the training phase, most managed self-infusion and reported satisfaction in managing therapy autonomously. Educating patients with neuropathies to self-infuse high-dose SCIG at home and with flexibility in dosing schedules was successfully demonstrated in this patient group.

Reference:


doi: 10.1097/NAN.0000000000000240.

Thank you to our partners for supporting IVTEAM